Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-13 18:30 |
RESULTS OF THE COMBINED GENERAL MEETING ON NOVEMBER 13, 2025
|
English | 165.6 KB | ||
| 2025-11-13 18:30 |
RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE MIXTE DU 13 NOVEMBRE 2025
|
French | 177.9 KB | ||
| 2025-06-04 07:00 |
Biophytis announces its participation in the BIO International Convention from …
|
English | 155.1 KB | ||
| 2025-06-04 07:00 |
Biophytis annonce sa participation à la BIO International Convention du 16 au 1…
|
French | 161.2 KB | ||
| 2025-05-30 22:00 |
Information on the Annual Financial Statements
|
English | 103.8 KB | ||
| 2025-05-30 22:00 |
Information sur les comptes annuels
|
French | 172.5 KB | ||
| 2025-05-15 07:00 |
Biophytis Highlights Innovative Approach to Obesity Treatment During Key ECO 20…
|
English | 144.3 KB | ||
| 2025-05-15 07:00 |
Biophytis met en lumière son approche innovante du traitement de l’obésité lors…
|
French | 129.9 KB | ||
| 2025-04-22 07:00 |
Biophytis cible la restauration de la mobilité chez les patients obèses
|
French | 143.1 KB | ||
| 2025-04-22 07:00 |
Biophytis targets mobility restoration in patients with obesity
|
English | 140.1 KB | ||
| 2025-04-09 07:00 |
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
|
English | 175.0 KB | ||
| 2025-04-09 07:00 |
Biophytis confirme le lancement de l’essai clinique de Phase 2 OBA dans l’obési…
|
French | 169.7 KB | ||
| 2025-03-28 22:00 |
Biophytis announces the settlement and delivery of its €2.6 million private pla…
|
English | 534.3 KB | ||
| 2025-03-28 22:00 |
Biophytis annonce le règlement-livraison de son placement privé de 2,6 millions…
|
French | 340.2 KB | ||
| 2025-03-26 07:35 |
Biophytis announces the successful completion of a €2,6 million private placeme…
|
English | 381.7 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
